Knowledge and Awareness Levels of Osteoporosis in Patients with Inflammatory Rheumatic Diseases
Öz
Anahtar Kelimeler
Kaynakça
- Sozen T, Ozisik L, Calik Basaran N. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46-56. Crossref
- Buttgereit F, Palmowski A, Bond M, et al. Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases. Nat Rev Rheumatol. 2024;20(7):417-431. Crossref
- Schett G, Kiechl S, Weger S, et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med. 2006;166(22):2495-2501. Crossref
- Mun H, Liu B, Pham THA, et al. C-reactive protein and fracture risk: an updated systematic review and meta-analysis of cohort studies through the use of both frequentist and Bayesian approaches. Osteoporos Int. 2021;32(3):425-435. Crossref
- Raterman HG, Lems WF. Pharmacological management of osteoporosis in rheumatoid arthritis patients: a review of the literature and practical guide. Drugs Aging. 2019;36(12):1061-1072. Crossref
- Briot K, Geusens P, Bultink IEM, et al. Inflammatory diseases and bone fragility. Osteoporos Int. 2017;28(12):3301-3314. Crossref
- Wiebe E, Huscher D, Schaumburg D, et al. Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis. 2022;81(10):1313-1322. Crossref
- Gendler PE, Coviak CP, Martin JT, et al. Revision of the osteoporosis knowledge test: reliability and validity. West J Nurs Res. 2015;37(12):1623-1643. Crossref
Ayrıntılar
Birincil Dil
İngilizce
Konular
Romatoloji ve Artrit
Bölüm
Araştırma Makalesi
Yazarlar
Alper Yıldırım
0000-0003-3160-458X
Türkiye
Yayımlanma Tarihi
17 Mart 2026
Gönderilme Tarihi
4 Ocak 2026
Kabul Tarihi
17 Şubat 2026
Yayımlandığı Sayı
Yıl 2026 Cilt: 9 Sayı: 1